secwatch.observer — SEC 8-K summary
======================================

Issuer:     SCYNEXIS INC (SCYX)
CIK:        0001178253
Form:       8-K
Filed at:   2022-03-29T23:59:59+00:00
Accession:  0001564590-22-012056
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SCYNEXIS reports 2021 net loss of $32.9M; BREXAFEMME revenues $1.1M in launch year
--------------------------------------------------------------------------------

- BREXAFEMME net product revenue $1.1M full-year, $0.6M Q4; cost of product revenue $0.3M full-year.
- Net loss $32.9M ($1.25/share) for FY2021 vs $55.2M ($5.15/share) in FY2020.
- Cash $104.5M at year-end; projected runway into Q2 2023; plus $9.7M non-dilutive in early 2022.
- Positive Phase 3 CANDLE for rVVC (65.4% vs 53.1% placebo, p=0.02); sNDA filing Q2 2022.
- Initiating MARIO Phase 3 for invasive candidiasis; Orphan Medicinal Product Designation from EMA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178253/000156459022012056/0001564590-22-012056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178253/000156459022012056/scyx-8k_20220329.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-012056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer